First detected in India, Omicron subvariant XBB.1.16 - also known as "Arcturus" - has already been reported in over 30 countries. This is what we know about it so far. The World Health Organization ...

A new COVID variant XBB.1.16, or "Arcturus", has now been identified in at least 34 countries including the UK. Arcturus is a subvariant of omicron and was first detected in India in January 2023.

Arcturus Therapeutics Holdings Inc. stock is down 46% since Sept. 2023 coverage; mRNA sector faces headwinds with public skepticism (35% comfortable with technology) and challenges translating success ...

Sept 23 (Reuters) - Biotech company Arcturus Therapeutics (ARCT.O), opens new tab sued AbbVie (ABBV.N), opens new tab in California federal court on Tuesday for allegedly stealing trade secrets ...

The new omicron variant XBB.1.16, better known as arcturus, is now responsible for about 14% of new Covid cases, per the latest data from the Centers for Disease Control and Prevention (CDC). That's ...

Arcturus Therapeutics specializes in mRNA medicines, targeting infectious diseases and rare disorders using proprietary technologies. Despite a financial dip post-Q2 2023, Arcturus remains financially ...

SAN DIEGO, April 10, 2025--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicine company focused on the development of ...

Arcturus Therapeutics believes it’s “highly unlikely” it will lose the promised government funding for its bird flu mRNA vaccine trial, despite reports swirling that Moderna’s own financial support ...

In a mixed interim data drop, Arcturus Therapeutics has revealed a lack of efficacy for its investigational inhaled mRNA therapy in cystic fibrosis (CF). The findings, shared today before market open, ...